Company Profile

Kazia Therapeutics Limited (NASDAQ: KZIA)
8:30 PM UTC, 10/11/24
Last: $0.41 Change: +0.00 %Change: +0.74% Volume: 148,264
Detailed Quote
Open: $ 0.40   Volume: 148,264
High: $ 0.41   Yield(%) 0.00
Low: $ 0.39   P/E Ratio (ttm): n/a
Dividend ($): 4.09   Market Cap ($): 9.45M
EPS ($) n/a   Shares Out: 23.63M
M = Million B = Billion
Price Performance
% Price Change (last 4 weeks): 16.31
% Price Change (last 13 weeks): -67.50
% Price Change (last 26 weeks): 11.94
% Price Change (last 52 weeks): -45.91
% Price Change (year to date): -8.99
Management Effectiveness
Return on Equity (%): -132.12
Return on Assets (%): -64.43
Return on Invested Capital (%): -84.17
Profitability
Gross Profit Margin (%): n/a
Net Profit Margin (%): n/a
Operating Profit Margin (%): 0.00
Price & Volume
50-day Moving Average: $0.38
200-day Moving Average: $0.34
Avg. Daily Vol. (last 50 days): 1,055,428
Avg. Daily Vol. (last 200 days): 4,564,552
52-wk high: $1.58
52-wk low: $0.19
Bid: $0.41
Ask: $0.42
Company Information
Kazia Therapeutics Ltd. is a clinical stage oncology company, which engages in the pharmaceutical research and development business. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.
Kazia Therapeutics Limited
Three International Towers 300 Barangaroo Avenue Level 24
Sydney NS 2000

Phone: 61.2.9472.4101
Fax: n/a
http://www.kaziatherapeutics.com
Per Share Data
Earnings (1year) ($): -0.44
Annual Dividend ($): 0.00
Current P/E Ratio (ttm): n/a
Book Value ($): 0.35
Cash Flow ($): -0.55
Valuation Ratios
Price/Earnings (x): n/a
Price/Sales (x): n/a
Price/Book (x): 3.30
Price/Cash Flow (x): n/a
Financial Strength
Quick Ratio (x): 1.42
Current Ratio (x): 1.42
LT Debt/Equity (x): 0.00
Total Debt/Equity (x): 14.91



Quotes displayed with 15 minutes delay. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. News provided by MT Newswires, a Division of MidnightTrader, Inc. Events Data provided by Wall Street Horizon. ©2021 Wall Street Horizon, Inc.